https://www.home.saxo/en-gb/markets/stocks/evmn-xnys
Evommune Inc stock | Saxo
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases.
evommuneincstocksaxo
https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update--evommune--aeromexico-begin-trading-302607261.html
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading
/PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market...
content advisorypre marketnyseupdateevommune
https://www.evommune.com/
Evommune | Novel Therapies for Chronic Inflammatory Disease
Nov 6, 2025 - Evommune is a clinical stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.
novel therapiesevommunechronicinflammatorydisease
https://www.biospace.com/evommune-announces-expanded-strategic-collaboration-with-maruho-to-develop-and-commercialize-mrgprx2-antagonist-evo756-in-greater-china-and-key-asian-countries
Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize...
Mar 20, 2024 - Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered...
strategic collaborationevommuneannouncesexpanded
https://www.biospace.com/press-releases/evommune-announces-top-line-data-from-phase-2-trial-of-evo756-in-chronic-inducible-urticaria-demonstrating-robust-activity-and-favorable-safety-profile
Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria...
https://www.fiercebiotech.com/biotech/ex-dermira-founders-pick-up-83m-series-a-to-advance-programs-licensed-from-lilly-s-dermira
Ex-Dermira founders pick up $83M for Evommune to advance programs in-licensed from Lilly's Dermira...
Sep 9, 2021 - Within a week of leaving Dermira after the dermatology medicines company
https://www.home.saxo/nb-no/markets/stocks/evmn-xnys
Evommune Inc aksje | Saxo Bank
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases.
evommuneincsaxobank